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ABSTRACT 
Objective: To investigate the cost-effectiveness (cost-utility) of introducing general 
practitioner screening for anxiety and depression in patients consulting with osteoarthritis 
(OA). 
Methods: A cluster-randomised trial-based economic evaluation to assess general 
practitioners screening for anxiety and depression symptoms in patients consulting with OA 
compared to usual care (screening for pain intensity) was undertaken over a 12-month period 
from a UK National Health Service and Societal perspective. Patient-level mean costs and 
mean quality-adjusted life years (QALYs) were estimated and cost-effectiveness 
acceptability curves controlling for cluster-level data were constructed. The base-case 
analysis used the net-benefit regressions approach. The two-stage non-parametric sampling 
technique was explored in a sensitivity analysis.  
Results: The base-case analysis demonstrated that the intervention was as costly as, and less 
effective than, the control (QALY diff, 95% CI: - 0.029 (95% CI -0.062 to 0.003)). In the 
base-case analyses, GP screening for anxiety and depression was unlikely to be a cost-
effective option (probability < 5% at £20,000/QALY). Similar results were observed in all 
sensitivity analyses.  
Conclusions: Prompting GP’s to routinely screen and manage comorbid anxiety and 
depression in patients presenting with OA is unlikely to be cost-effective. Further research is 
needed to explore clinically-effective and cost-effective models of managing anxiety and 
depression in patients presenting with clinical OA. 
 
 
Key words economic evaluation, cost-effectiveness, cost-utility, osteoarthritis, depression, 
anxiety, screening, and case-finding 
 
Trial registration: ISRCTN registry ISRCTN40721988 
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SIGNIFICANCE AND INNOVATIONS  
 
 This is the first economic evaluation assessing general practitioner (GP) screening for 
anxiety and depression in older people with OA alongside pain intensity.  
 
 This economic evaluation showed routine screening for anxiety and depression by 
GPs is unlikely to be cost-effective in patients with osteoarthritis. 
 
 Further research is needed to explore cost-effective models of managing anxiety and 
depression in patients presenting with clinical OA. 
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INTRODUCTION 
Osteoarthritis (OA) is a common cause of persistent pain, disability and poor quality of life in 
older adults. It is estimated that approximately 1 million adults in the UK consult for OA 
each year [1]. OA has negatively impacted the economy of the United Kingdom (UK) with 
direct and indirect costs between 0.25% and 0.50% of Gross National Product (GNP) [2-3]. 
Direct costs of OA treatment are driven mainly by total joint arthroplasty (TJA), while 
indirect costs are mostly driven by the loss of productivity due to absenteeism from paid 
work [4-5]. Among other factors, persistent pain and disability related symptoms have been 
linked with increased levels of anxiety and depression in patients with OA who experience 
subsequent worse outcomes [6-7]. Patients with OA and associated depression use more 
medication and are likely to have increased healthcare resource utilisation [8-9]. Depression 
is also a major cause of work-related absenteeism and diminished or reduced productivity 
[10].  
 
Case-finding for depression in primary care has been recommended as a means of improving 
the identification of depressive symptoms and consequently improving overall quality of life 
and OA-related pain outcomes [11]. Case-finding for depression in patients with chronic 
physical disease such as OA has been recommended in guidelines by the National Institute 
for Health and Care Excellence (NICE) [12-13], however these guidelines did not consider 
the costs and benefits of such strategies. There have been calls to investigate the effectiveness 
and cost-effectiveness of case-finding for anxiety and depression in patients with OA in 
primary care [14], although, to date, such evidence remains limited [15-16].  
 
We conducted an economic evaluation alongside a randomised controlled trial to establish the 
cost-effectiveness of introducing general practitioner (GP) screening for anxiety and 
depression in older patients consulting for OA. The trial and its clinical findings have been 
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reported in full elsewhere [18]. In this paper we report the cost-effectiveness (cost-utility) 
analysis, giving specific attention to a comparison of alternative methodological approaches 
to analysing cost-effectiveness data from cRCTs.  
 
MATERIALS AND METHODS 
Overview 
The economic evaluation took the form of a cost-utility analysis alongside a cRCT over a 12 
month follow-up period. Randomisation was conducted at the GP practice level in order to 
prevent contamination between the two arms and participating GPs [19]. The NHS 
perspective was adopted in the base case analysis. Ethical approval for this study was 
obtained from the Black Country Research Ethics Committee (reference number 
11/WM/0093) and all participants gave informed consent to participate in the study. Primary 
care resource data were obtained from reviewing medical records while secondary care 
resource use data were collected via structured patient questionnaires at baseline and at two 
follow-up points: 6 months, and 12 months. Given the length of follow-up was 12 months, 
neither costs nor outcomes were discounted. The primary outcome for clinical effectiveness 
was patient-reported current pain intensity on a 0-10 numerical rating scale [20], and the 
primary time-point was across 12 months post-consultation. Full details of the trial methods 
and results have been previously published [18]. 
Interventions 
Patients in GP practices implementing the intervention were screened by GPs at point-of-care 
for anxiety, depression and current pain intensity with the aid of an electronic template linked 
with patient records, which appeared following entry of a Read code for an OA related 
condition. The template incorporated a two-item brief depression tool (Patient Health 
Questionnaire [PHQ] [21]; and a two-item ultra-brief anxiety assessment tool (Generalised 
Anxiety Disorder [GAD]) [22]. Negative responses to the anxiety and depression questions 
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were used to rule out a potential depression or anxiety diagnosis. The template then prompted 
GPs to follow NICE clinical guidelines on the management of OA, anxiety and depression in 
patients with physical health problems [23-25]. The control involved point-of-care current 
pain intensity assessment prompted by the electronic template but involving only the item on 
current pain intensity. We calculated participant-specific costs for the intervention based on 
information collected within the trial. This was determined by asking participating GPs about 
any additional time they used for screening for anxiety and depression. Intervention costs 
were then estimated based on an average 1.29 additional minutes of GP time for screening 
participants based on a mean of the summary of responses from the participating GPs in the 
GP questionnaire survey.  
 
Outcome measures 
We used the EuroQoL-5D-5L (EQ-5D-5L) valued using the UK value set derived from a UK 
general population survey [26-27] to estimate quality-adjusted life years (QALYs) gained 
using the area-under-the-curve approach [28]. Imbalances in baseline EQ-5D-5L utility 
scores were controlled for using a multiple regression-based adjustment [29]. This approach 
allows for estimation of differential QALYs and facilitates prediction of adjusted QALYs, 
while controlling for base-line utility values.  The model included the treatment arm dummy 
variable and patient specific baseline utility values [29]. The primary outcome for the trial 
was patient-reported current pain intensity on a 0-10 numerical rating scale [19] across 12 
months post-consultation. All outcomes were measured at baseline, 3 months, 6 months and 
12 months and were obtained from a self-completed questionnaire administered at these time 
points. 
Resource use and costs 
In the base-case analysis, costs were measured from the UK NHS perspective, with overall 
societal costs considered in the sensitivity analysis. Information about resource use related to 
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OA, anxiety and depression was collected from general practice records and self-reported 
questionnaires. Primary care resource use was obtained from a review of medical records 
covering the full 12-month follow-up period for patients who provided consent, and included 
primary care contacts and prescribed medications.Patient level data on primary care consultations 
(from GP records) at which OA, anxiety and depression were mentioned were noted and recorded by 
type of consultation and type of professional seen. Secondary care resource use data were 
collected via self-report postal questionnaires administered at 6 months and 12 months. 
Secondary care contacts included visits to other healthcare professionals (e.g. hospital 
consultants, physiotherapists, counsellors, and psychologists), hospital-based investigations 
(e.g. X-rays, MRI scans), and procedures (injections, surgeries). Non-NHS (healthcare) costs 
were assessed by obtaining information on patient’s purchase of over-the-counter medicines, 
treatments or appliances and their use of private healthcare using postal self-report 
questionnaires. Self-reported data on time off work and occupation were also collected in 
order to assess broader economic consequences. Table 1 provides the unit costs and sources 
used to value healthcare resources. Unit costs were obtained from the published British 
National Formulary (BNF) [30] for estimating the cost of prescribed medication, and the 
NHS Reference costs [31] and Unit Costs of Health and Social Care [32] for primary and 
hospital-based resource use items. Productivity costs were estimated using the human capital 
approach and salary costs were based on mean weekly earnings by age and sex and UK 
Standard Occupational Classification coding [33-35]. All costs were expressed in 2013/2014 
UK prices. 
 
Statistical Analysis 
We explored the amount of each resource used by patients in each group using frequencies, 
means and standard deviations. The statistical analysis was conducted on an intention to treat 
basis, and in accordance with current cRCT guidelines [36].  The analysis involved adopting 
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multilevel modelling statistical techniques taking into consideration clustering in the cost and 
effect data [36-37].The multiple imputation technique using predictive mean matching was 
used to impute all missing values for the EQ-5D and cost data [38]. The imputation model 
included age, gender, treatment group, and were based on M=25 imputed datasets.  
 
Separate generalised equation models, controlling for clustering were used to estimate the 
mean incremental costs and QALYs for the intervention relative to the control. Uncertainty 
was examined by estimating 95% confidence intervals (CIs) and cost-effectiveness 
acceptability curves (CEACs), which link the probability of the GP screening intervention 
being cost-effective to a range of potential threshold values (λ) that the health system may be 
willing to pay per additional QALY gained [36,39-40]. Dependent variables in the multilevel 
models included costs, QALYs and net monetary benefits (NMB) and model co-efficient 
estimates of differences in these variables were used as part of the incremental analysis. 
Statistical analysis was performed using Stata V.12 [41].  
 
Cost-effectiveness analytical approach 
In the base-case analysis, CEACs were estimated using a NMB regression approach [42]. The 
NMB allows costs and outcomes to be considered on the same monetary scale. NMB was 
defined as λ x (Δ effecti) - Δ costi, where Δ effecti is the incremental person-level outcome 
associated with the screening intervention, and (Δ costi), the additional costs due to screening 
for anxiety and depression, and λ=willingness to pay per unit of outcome gain. Using the 
output, we plotted CEACs, showing the likelihood that the screening intervention is cost 
effective given different assumptions about willingness to pay for outcomes. The regression 
analysis adopted methods reflecting the cluster randomised nature of the trial [36-37], by 
using a regression-based model of net benefits, with general practice as the cluster identifier. 
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Sensitivity analysis 
Sensitivity analyses were performed to assess uncertainty and robustness of the findings. 
Firstly, CEACs were estimated by using a two-stage non-parametric bootstrapping technique 
for comparison purposes [40, 43]. This approach accounts for clustering between the 
hierarchical cost and effects data. The 2-stage bootstrapping output from STATA  reports the 
cost-effectiveness probabilities for a range of potential threshold values used to estimate the 
probability that the intervention was cost-effective. Secondly, results were presented from a 
societal perspective, taking into account productivity costs. Thirdly, a complete-case analysis 
was carried out to assess the impact of missing cost and EQ-5D-5L data.  
 
RESULTS 
Overview 
Overall, 45 general practices were randomised, 24 to the control group and 20 to the 
intervention group, with a mean practice list size of 7,397 and 5,850 in the control and 
intervention groups respectively. In all, 7,279 patients were identified as being eligible and 
after appropriate exclusions, 2,042 patients were mailed a post-consultation questionnaire.  
Individual participants recruited from the intervention and control practices had broadly 
similar characteristics. A summary of participation rates, by arm and participant baseline 
characteristics is given in supplementary tables S1 and S2. A total of 1412 participants 
returned questionnaires (n=501 (35%) from 20 intervention practices, 911 (65%) from 24 
control practices) and were considered for the base-case analysis. Complete primary care 
resource data from GP records were available for 1235 participants (87%), while complete 
secondary care resource data were available for 985 (70%) participants who returned 
questionnaires at both 6 and 12 months. Complete QALY data at baseline, 6 and 12 months 
was available for 573 (63%) intervention and 307 (61%) control patients. Following the 
multiple imputation procedure, all 1412 participants were included in the base-case analysis. 
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The mean age of participants was 65, with slightly more women (57%); they were 
overwhelmingly white (97%) and just over 30% were in paid employment.  
 
Resource use  
Table 2 shows the disaggregated details of mean resource use for participants with complete 
resource use data. Service use was summarised under broad categories, and individual items 
of service use were not imputed. There were minimal differences between the two groups in 
terms of healthcare use, but GP visits for depression, anxiety and OA were slightly higher 
among intervention participants, as were visits to other NHS professionals for any reason 
(2.86 vs 2.42 and 0.26 vs 0.13). Similar findings were observed when considering a societal 
perspective with the exception of significantly higher reported time-off work in the control 
group at 12 months (15 days vs 8.3 days).  
 
Healthcare costs and productivity costs 
Tables 2 and 3 summarise the mean cost per patient, by group, for each category of cost. All 
available data are included for each category. Comparing the two groups, there were small 
differences in the costs, with the exception of significant differences in costs to other 
healthcare professionals (such as occupational therapists, acupuncturists and chiropractors) 
and productivity loss. NHS, healthcare and societal costs were similar in both groups, 
although slightly higher in the control arm. Adjusting for clustering in costs resulted in 
negligible differences between the groups.  
 
At 12 months follow-up, 98 (26.4%) in the intervention and 182 (28.2%) in the control group 
were in paid employment. Of those reporting being in employment, 75 (11.6 %) patients in 
the intervention group reported time off paid work compared with 35 (9.4%) in the control 
group. Over a period of 12 months follow-up, the mean days-off work taken was higher in the 
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control arm (15.0 days) than the intervention arm (8.3 days), and this translated to higher 
productivity costs in the control arm compared to the intervention arm (Table 2). 
 
Health outcomes 
The results for analysis of the health outcome measures (mean EQ-5Ds and QALYs) are 
shown in Tables 3.  In terms of QALYs gained at 12 months the mean estimates were 0.686 
for the screening intervention and 0.711 for the control, showing higher QALY scores for the 
control group after adjusting for baseline differences. A similar result was observed in the 
unadjusted QALY scores.   
 
Estimation of Cost-effectiveness 
Estimates showed that the intervention was associated with lower QALYs and that the 
adjusted difference in cost between the two groups was minimal (£1.02 lower in intervention 
arm).  
 
Net monetary benefit regression approach  
The mean cost and outcome results of the cost-utility analysis based on the net-monetary 
benefit approach and forming the base-case analysis are presented in Table 3. The findings 
indicate that there is very low probability (< 10%) of the intervention being cost-effective at 
conventional willingness to pay thresholds for additional QALYs (£20,000 to £30,000 per 
QALY). Figure 1 presents the probability that the screening intervention would be seen as 
cost-effective using a CEAC for different values of willingness to pay from an NHS and 
societal perspective based net-monetary benefit approach.  
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Sensitivity analysis  
2-stage non-parametric bootstrap analysis: Similar results were observed when using the 2-
stage non-parametric bootstrap approach. The probability of the intervention being cost-
effective remained low (<10%) at conventional willingness to pay threshold for additional 
QALYs. The output results from this approach were however slightly lower than the net-
monetary benefit approach (Figure 2).  The analysis conducted from a societal perspective 
showed results were broadly similar to the findings in the base-case analysis (Figures 1 and 
2). The results from the complete-case sensitivity analysis are presented in the supplementary 
files: S3 Table and S1-S2 Figures. The results from these analyses were generally consistent 
with the findings from the base-case analysis, with the intervention as costly as but less 
effective than the control. The only exception was that the intervention was associated with a 
slightly higher probability of being cost-effective (20%) in both approaches when compared 
to the base-case analysis.  
 
DISCUSSION 
This paper reports a cost-utility analysis of introducing GP screening for anxiety and 
depression in older patients consulting for OA, and an assessment of alternative analytical 
approaches for economic evaluation of cRCTs. The results showed that GP screening for 
anxiety and depression in OA patients is unlikely to be a cost-effective option, and similar 
results are observed regardless of the perspective or approach adopted for the economic 
analysis. There was minimal difference between the two groups in terms of costs, and the 
finding that additional screening for anxiety and depression is unlikely to be cost-effective is 
primarily based on the evidence that shows slightly higher QALYs in the control group. The 
results supplement the main trial findings that found a small, statistically significant 
difference in the direction of worse pain outcomes among those screened for depression and 
anxiety compared to those not screened [18]. Further exploration of this using probability 
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bias analysis suggests this could plausibly be attributed to selection bias [44]. In both 
analytical approaches considered, probability of GP screening for anxiety and depression 
being cost-effective remained low (<30%) at the recommended NICE thresholds of £20,000 
to £30,000 [45].  
 
This is the first economic evaluation assessing GP screening for anxiety and depression in 
older people with OA alongside pain intensity.  It was based on a large sample of a wide-
range of clinically diagnosed OA in patients (n=1412) across a number of locations (45 
practices). Resource use information was collected using a combination of GP records and 
self-reported data, including information outside the main NHS perspective, and therefore 
reports comprehensive resource use data. However, a limitation of using self-report data only 
is that respondents could potentially under-report resource utilisation, particularly over longer 
periods of recall [46-47]. A further strength is that it can be argued that the use of the QALY 
measure in the cost-effectiveness analysis may have captured a broader range of effects of 
screening than the pain measure used in the clinical paper, given that it includes dimensions 
of pain, mobility, anxiety and depression. Also, the analysis used a pragmatic and rigorous 
study design, and employed comparative statistical methods for analysing cost-effectiveness 
data alongside cluster trials based on recommended methods [36, 48]. However, there are 
also some limitations. The amount of missing data in the primary care and secondary care 
data requiring imputation may be of concern. Response rates for the secondary care costs 
(70% at 12 months) and QALYs (62 % over 12 months) were relatively low. Multiple 
imputation using predictive mean matching was used to address potential biases resulting 
from incomplete data. However, a limitation of this approach is that it does not take into 
consideration the multi-level structure of the data. Moreover, the imputation model specified 
could have included a wider set of variables, and covariates. Results of the base-case 
(imputed) and complete-case analysis were comparable in regard to policy implications.  
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Evidence supporting effectiveness of screening for anxiety and depression in patients with 
OA remains limited and with contradictory findings [49, 14, 18]. No previous studies have 
assessed the cost-effectiveness of GP screening for anxiety and depression alongside pain 
intensity in patients with OA at risk of depression. Our study in line with findings from a 
previous review [16] suggests that screening for anxiety and depression in general is unlikely 
to be a cost-effective option.  
 
Few studies have attempted to compare alternative methods for the economic analysis of 
cRCTs [48], although methodological guidance on the use of these methods to analyse data 
from cRCTs has been established. The analysis reported in this article reported similar 
findings from the different approaches explored (net-monetary benefit approach and 2SB). 
The results obtained here may not be generalizable to another disease or context. There is 
need for further empirical studies exploring alternative methods of analysing cRCTs in other 
disease areas or contexts.   
 
Our results show that people receiving a screening intervention for depression, anxiety and 
pain intensity were associated with higher primary care costs, but lower hospital and 
productivity loss costs. However, patients receiving the screening intervention were 
associated with slightly lower quality of life outcomes. The economic evaluation 
demonstrated that adding routine screening for anxiety and depression compared to usual care 
is not a cost-effective option for people with OA. The study has broader implications in 
depression case-finding interventions targeted at patients with OA, particularly with the 
assumption that such services are money saving to the NHS and improve overall OA-related 
health outcomes. Here, productivity and hospital cost savings were observed, but the 
probability of overall cost-effectiveness was judged very low at recommended ICER 
thresholds.  
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Nonetheless, given the significant costs associated with OA and the increased risks of anxiety 
and depression in this group of patients, future research should explore the costs and benefits 
of appropriate management strategies for anxiety and/or depression once detected in patients 
presenting with clinical OA in primary care. It would also be helpful to assess ways of 
identifying those anxiety or depressive symptoms that are likely to make future management 
services both less cost-effective and more costly.  
 
ACKNOWLEDGEMENTS 
This project was undertaken with the support of Keele Clinical Trials Unit, Keele University, 
UK. We would like to thank all participating patients and general practices.  
 
DISCLOSURE STATEMENT: None of the authors have financial relationships with any 
organisations that might have an interest in the submitted work and declare no other 
relationships or activities that could appear to have influenced the submitted work. 
 
The views expressed in this paper are those of the author(s) and not necessarily those of the 
NHS, the NIHR, or the Department of Health. 
 
 
 
 
 
 
 
 
 
Arthritis Care and Research 
 
17 
 
REFERENCES 
1. Arthritis Research UK. Osteoarthritis: An Information Booklet. 2004.  
2. Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: a systematic 
review of cost-of-illness studies. Semin Arthritis Rheum. 2015; 44: 531–41. 
3. Xie, F., Kovic, B., Jin, X. et al. Economic and Humanistic Burden of Osteoarthritis: A 
Systematic Review of Large Sample Studies. Pharmacoeconomics. 2016.34: 1087-
1100. doi: 10.1007/s40273-016-0424-x.  
4. Chen, C. Gupte, K. Akhtar, P. Smith, J. Cobb. The global economic cost of 
osteoarthritis: how the UK Compares. Arthritis. Arthritis, 2012 (2012), p. 698709 
http://dx.doi.org/10.1155/2012/698709. 
5. Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, et al. 
Health economics in the field of osteoarthritis: an expert's consensus paper from the 
European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013; 43 (3):303-13. doi: 
10.1016/j.semarthrit.2013.07.003.  
6. Buszewicz MJ, Chew-Graham C. Improving the detection and management of anxiety 
disorders in primary care. Br J Gen Pract. 2011; 61(589):489-90. 
7. Sharma, A., Kudesia, P., Shi, Q., & Gandhi, R. Anxiety and depression in patients 
with osteoarthritis: impact and management challenges. Open Access Rheumatology : 
Research and Reviews. 2016; 8:103–113. http://doi.org/10.2147/OARRR.S93516. 
8. Rosemann T, Gensichen J, Sauer N, Laux G, Szecsenyi J. The impact of concomitant 
depression on quality of life and health service utilisation in patients with 
osteoarthritis. Rheumatology Int. 2007; 27(9):859-63. 
9. Yohannes MA & Caton S. Management of depression in older people with 
osteoarthritis: A systematic review, Aging & Mental Health.2010; 14:6, 637-651, 
DOI: 10.1080/13607860903483094.   
Arthritis Care and Research 
 
18 
 
10. Evans-Lacko, S and Knapp, M. Global patterns of workplace productivity for people 
with depression: absenteeism and presenteeism costs across eight diverse countries. 
Social Psychiatry and Psychiatric Epidemiology. 2016; 51(11): pp 1525–1537. 
11. Lin EH, Tang L, Katon W, Hegel MT, Sullivan MD, Unutzer J. Arthritis pain and 
disability: response to collaborative depression care. Gen. Hosp. Psychiatry. 2006; 
28(6):482-486. 
12. National Institute for Health and Clinical Excellence. The care and management of 
osteoarthritis in adults. 2008; Clinical guidelines CG59. 
13. National Institute for Health and Clinical Excellence. Depression in adults with a 
chronic physical health problem: recognition and management. 2009; (CG91).  
14. Gilbody S, Sheldon T, House A. Screening and case-finding instruments for 
depression: a meta-analysis. CMAJ. 2008; 178(8):997-1003. 
15. Roy-Byrne P, Sullivan MD, Sherbourne CD, Golinelli D, Craske MG, Sullivan G, et 
al. Effects of pain and prescription opioid use on outcomes in a collaborative care 
intervention for anxiety. Clin J Pain. 2013; 29(9):800-6. 
16. Thombs BD, Roseman M, Coyne JC, de Jonge P, Delisle VC, Arthurs E, et al. Does 
evidence support the American Heart Association’s recommendation to screen 
patients for depression in cardiovascular care? An updated systematic review. PLoS 
ONE. 2013; 8:e52654. https://doi.org/10.1371/journal.pone.0052654 PMID: 
23308116. 
17. Thombs BD, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JP. There are no 
randomized controlled trials that support the United States Preventive Services Task 
Force Guideline on screening for depression in primary care: a systematic review. 
BMC Med. 2014; 12:13. https://doi.org/10.1186/1741-7015- 12-13 PMID: 24472580. 
18. Mallen CD, Nicholl BI, Lewis M, Bartlam B, Green D, Jowett S, et al. The effects of 
implementing a point-of-care electronic template to prompt routine anxiety and 
Arthritis Care and Research 
 
19 
 
depression screening in patients consulting for osteoarthritis (the Primary Care 
Osteoarthritis Trial): A cluster randomised trial in primary care. PLoS Med.2017; 
14(4):e1002273. https://doi.org/10.1371/journal.pmed.1002273.  
19. Torgerson David J. Contamination in trials: is cluster randomisation the answer? BMJ 
2001; 322:355–7. 
20. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. 
Pain 1992; 50(2):133-49.  
21. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. 
Two questions are as good as many. J Gen Intern Med. 1997; 12:439±45. 
https://doi.org/10.1046/j.1525-1497. 1997.00076. x PMID: 9229283.  
22. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in 
primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 
2007; 146:317±25. PMID: 17339617 
23. National Collaborating Centre for Chronic Conditions (NCCCC). Osteoarthritis: 
National Clinical Guideline for Care and Management in Adults. London: Royal 
College of Physicians. 2008; Report No: CG59.  
24. National Collaborating Centre for Mental Health. Depression in adults with a chronic 
physical health problem. Treatment and management (NCCMH). London: The British 
Psychological Society and The Royal College of Psychiatrists; 2009. Report No.: 
National Institute for Health & Clinical Excellence National Clinical Guideline 91.  
25. National Institute for Health and Care Excellence. Generalised anxiety disorder in 
adults: management. NICE clinical guideline 113. London: National Institute for 
Health and Clinical Excellence; 2011. 
26. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the 
new five-level version of EQ-5D (EQ-5D-5L) Quality Life Res. 2011;20:1727–36. 
Arthritis Care and Research 
 
20 
 
27. Devlin, N., Shah, K., Feng, Y., Mulhern, B. and Van Hout, B. Valuing Health-Related 
Quality of Life: An EQ-5D-5L Value Set for England. Office of Health Economics. 
Research Paper. 2016. 
28. Morris S, Devlin N, Parkin D. Economic Analysis in Health Care John Wiley and 
Sons Chichester. 2007. 
29. Manca A, Hawkins N, Sculpher J. Estimating mean QALYs in trial-based cost-
effectiveness analysis: The importance of controlling for baseline utility. Health Econ. 
2005; 14; 487-496.  
30. British Medical Association, Royal Pharmaceutical Society of Great Britain. British 
National Formulary. 66th ed. London BMJ Books, 2013.  
31. Department of Health. NHS Reference Costs 2012/2013: 
https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 
32. Curtis L. Unit Costs of Health and Social Care. Personal Social Services Research 
Unit. 2013: http://www.pssru.ac.uk/project-pages/unit-costs/2013/ 
33. SOC. Standard Occupational Classification. www.ons.co.uk. 2010.  
34. ASHE. Annual Survey of Hours and Earnings. Available at: http://www.ons.gov.uk. 
2013. 
35. Knies S, Severens JL, Ament AJ, Evers SM. The transferability of valuing lost 
productivity across jurisdictions. Differences between national pharmacoeconomic 
guidelines. Value Health 2010; 13(5):519-527. 
36. Gomes M, Ng ESW, Grieve R, Nixon R, Carpenter J, and Thompson SG: Developing 
appropriate methods for cost-effectiveness analysis of cluster randomized trials. Med 
Decis Making 2012, 32:350-361.  OpenURL  
37. Ng ES, Diaz-Ordaz K, Grieve R, Nixon RM, Thompson SG, Carpenter JR: Multilevel 
models for cost-effectiveness analyses that use cluster randomised trial data: an 
Arthritis Care and Research 
 
21 
 
approach to model choice. Stat Methods Med Res 2013. doi: 
10.1177/0962280213511719. [Epub ahead of print] 
38. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999; 8:315. 
39. Hoch JS, Briggs AH, Willan AR: Something old, something new, something 
borrowed, something blue: a framework for the marriage of health econometrics and 
cost-effectiveness analysis. Health Econ 2002, 11:415-430 
40. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J 
Psychiatry 2005; 187:106-108. 
41. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP. 
2009. 
42. Glick H. Economic evaluation in clinical trials. Oxford University Press, 2007. 
43. Ng ES, Grieve R, Carpenter J: Two-stage non-parametric bootstrap sampling with 
shrinkage correction for clustered data. Stata J 2013, 13:141-164.   
44. Barnett LA, Lewis M, Mallen CD, Peat G. Applying quantitative bias analysis to estimate the 
plausible effects of selection bias in a cluster randomised controlled trial: secondary analysis 
of the Primary care Osteoarthritis Screening Trial (POST). Trials. 2017 Dec 4; 18(1):585. doi: 
10.1186/s13063-017-2329-1 
45. McCabe C, Claxton K and Culyer AJ. (2008) The NICE cost-effectiveness threshold: 
what it is and what that means. Pharmacoeconomics 26: 733-744. 
46. Petrou S, Murray L, Cooper P, et al. The accuracy of self-reported healthcare resource 
utilization in health economic studies. Int J Technol Assess Health Care 2002; 
18:705–10. 
47. Bhandari A, Wagner T. Self-reported utilization of health care services: improving 
measurement and accuracy. Med Care Res Rev 2006; 63:217-35. 
Arthritis Care and Research 
 
22 
 
48. Bachman MO, Fairall L, Clark A et al. (2007). Methods for analysing cost-
effectiveness data from cluster randomised trials. Cost effectiveness resource 
allocation. 5, 12.  
49. Hickie, I.B., Davenport, T.A., Ricci, C.S., 2002. Screening for depression in general 
practice and related medical settings, beyond blue: the national depression initiative. 
MJA; 177, S111–S116. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arthritis Care and Research 
 
23 
 
Tables 
Table 1: Unit costs and data sources  
Health care resource Unit cost (£) 
Primary care
a
  
GP consultation per 11.7 minutes 34 
Practice nurse consultation per hour 44 
Nurse home visit per hour 60 
Community physiotherapist per hour 30 
Secondary care contacts
b
  
Orthopaedic surgeon 128 
Rheumatologist 202 
Massage therapist 49 
Physiotherapist 49 
Osteopath 49 
Mental Health Nurse 34 
Chiropractor 49 
Psychiatrist 283 
Psychologist 264 
Intervention cost  
Extra-time to complete prompt: 1.29 
minutes 
2.91 
Prescribed Medication Patient-specific 
c
 
Medical investigations/Interventions Patient-specific 
b
 
Time-off work Mean national wage by age and sex
d 
 
a Curtis L Unit Cost of Health and Social Care 2013 PSSRU,  
b NHS Reference costs schedule 2012/2013,  
c British National Formulary, ASHE (2013) Annual Survey of Hours and Earnings. 
Available at: http://www.ons.gov.uk 
 
 
 
 
Arthritis Care and Research 
 
24 
 
Table 2: Health care resource use and costs by trial arm*.  
 
Resource/cost component 
Resource use (units) Cost (£) 
Control 
N = 633 
Intervention 
N = 352 
Control 
N = 633 
Intervention 
N = 352 
Primary care
†
:     
  General practitioner 2.42 (2.07)** 2.86 (2.25)** 80.92 (68.19) 94.38 (73.23) 
  Practice nurse 0.03 (0.18) 0.03 (0.17) 0.23 (1.57) 0.27 (1.55) 
  Other 0.07 (0.34) 0.04 (0.20) - 0.14 (1.67) 
Secondary care
††
:      
Appointments NHS 
consultant 
2.07 (4.38) 1.69 (2.94) 134.93 (262.94) 
112.45 
(207.82) 
Appointments with private 
consultant 
0.44 (1.93) 0.41 (1.70) 23.48 (104.19) 21.13 (80.89) 
Appointments with ‘other’ 
professionals in NHS 
hospitals 
0.13 (0.53)** 0.26 (1.24)** 10.58 (36.41) 17.48 (48.47) 
Appointments with ‘other’ 
professionals in private 
hospitals 
0.06 (0.56) 0.05 (0.50) 0.07 (1.74) 0.25 (3.31) 
Investigations and 
treatments 
a††
 
372 (58.8) 197 (55.9) 
377.21 
(1153.01) 
353.33 
(1014.55) 
Prescriptions n (%) n (%)   
Proportion received 
anxiety/depression 
prescription  
150 (19%) 100 (23%) - - 
Proportion received OA 
prescription 
567 (71%) 343 (78%) - - 
Prescribed Medication 
- - 225.49 (205.80) 
225.59 
(190.22) 
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Over-the-counter 
medicines/treatments 
a††
 
373 (58.9) 201 (57.10) 13.55 (50.29) 14.10 (58.46) 
Productivity loss/costs
b
  
15.01 (31.96) 8.34 (16.95) 
1094.87 
(2530.32) 
644.25 
(1460.85) 
Productivity costs
c
 
  
310.74 
(1441.57) 
174.59 
(816.72) 
Values are mean (sd) resource use and costs (£) per patient, by treatment group, for patients 
providing health care utilisation data), unless stated otherwise. †  Data based on medical records 
review of available data and includes anxiety/depression and OA related healthcare use †† Data 
based on self-reported questionnaires at 6 and 12 months and includes secondary healthcare use for 
any health reason. a The number (%) of participants reporting usage within the procedures, 
investigations, procedures, over-the-counter medicines and prescribed medication categories are 
reported instead of mean (SD) because of multiple usage, purchases and/or prescriptions over 12 
months. ** Significant differences between the groups as the value zero is not contained in the 95 % 
confidence interval. Confidence intervals for mean differences in resource use were obtained by bias 
corrected and accelerated non-parametric bootstrapping using 1000 replications.  
b The indirect costs are based on the subsample of respondents in paid employment at 12 months  
(n = 280).  
c Indirect costs based on the complete-case dataset (n = 985) 
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Table 3: Cost-Utility analysis using the net-benefit regression approach
 †    
 
 Control Intervention Incremental Analysis 
(Intervention versus 
Control) 
*Mean differences (95% 
CI’s) 
N=911 N=501  
COST ANALYSIS†    
NHS cost (£) 
Mean (Standard 
Deviation) 
759.74 
(1152.38) 
744.09 
(1008.36) 
1.02 
(-135.96 to 138.02) 
Healthcare cost (£) 
Mean (Standard 
Deviation) 
794.73 
(1163.13) 
777.75 
(1031.82) 
2.70 
(-138.28 to 143.69) 
Societal cost (£) 
Mean (Standard 
Deviation) 
1071.69 
(1866.80) 
946.34 
(1351.82) 
-122.29 
(-318.50 to 73.91) 
EFFECTIVENESS  ANALYSIS†  
Unadjusted QALYs 
gained* 
Mean (Standard 
Deviation) 
0.715 
(0.216) 
 
0.679 
(0.220) 
 
-0.029 
(-0.062 to 0.003)  
[p=0.072] 
Adjusted QALYs 
gained* 
0.711 0.686  
COST EFFECTIVENESS 
ANALYSIS 
Probability that Treatment is Cost Effective at λ 
Threshold Value (λ)  
Estimate 
NHS Societal 
λ = £0 51% 89% 
λ = £5,000 4% 36% 
λ = £10,000 3% 16% 
λ = £15,000 3% 10% 
λ = £20,000 3% 8% 
λ = £25,000 3% 7% 
λ = £30,000 3% 6% 
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λ = £35,000 3% 6% 
λ = £40,000 3% 5% 
NHS, National Health Service, QALY, Quality-Adjusted Life Year. * Mean differences adjusted 
for clustering in cost and QALY outcomes. 
† Imputed dataset 
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Figures 
 
Figure 1: Cost-effectiveness acceptability curve for the comparison of case-finding versus 
pain only based on the net-monetary benefit regression approach  
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Figure 2: Cost-effectiveness acceptability curve for the comparison of case-finding versus 
pain only based on the two-stage bootstrap sampling process.  
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Supplemental tables  
 
S1 Table: Summary of participation rates, by arm 
 Control Intervention 
Number of practices randomised and received 
intervention 
24 20 
Practice list size, mean (SD)
 †
 7,397 (4,250) 5,850 (2,693) 
Total number of potentially eligible patients 4238 3041 
Ineligible/excluded/declined/refused 2899 2338 
Mailed post-consultation questionnaire 1339 703 
Returned post-consultation questionnaire 911 501 
Returned follow-up questionnaire at 3 months 708 385 
Returned follow-up questionnaire at 6 months 686 378 
Returned follow-up questionnaire at 12 months 646 371 
† Practice allocation was based on a minimisation algorithm, with the average practice list 
size in the control higher than that of practices in the intervention group.  
 
 
 
S2 Table: Participant baseline characteristics, by arm 
 Control Intervention 
Age (years), mean (SD) 24 20 
Female, n (%) 7,397 (4,250) 5,850 (2,693) 
Currently in a paid job, n (%) 286 (31) 166 (33) 
Self-reported body mass index (kg/m2), mean 
(SD) 
28.7 (5.5) 28.6 (5.1) 
Comorbidity†, n (%) 666 (73) 370 (74) 
First pain consultation episode, n (%) 355 (40) 163 (33) 
Pain score at time of consultation (0-10), mean 
(SD) 
6.3 (2.1) 6.3 (2.0) 
†Any of the following self-reported conditions: previous heart attack of stroke, angina, raised 
blood pressure, diabetes, circulation problems in legs, cancer, liver disease, kidney disease, 
asthma/bronchitis, deafness, or eyesight problems 
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S3 Table: Cost-utility analysis using the net benefit-regression approach    
COST ANALYSIS 
 
Control Intervention  
 N=633 N=352 
NHS cost (£) 
Mean (Standard Deviation) 
795.45 (1291.72) 770.40 (1112.73) 
 Incremental Analysis 
(Intervention versus Control) 
Adjusted NHS Cost (£) 
Difference in Means (95% CI’s)  
 
-23.05 (-189.22 to 143.14) 
EFFECTIVENESS ANALYSIS 
 
Control Intervention  
 N=573 N=307 
   
EQ-5D scores (complete-cases)   
Baseline 0.5888 (0.2440) 0.5757 (0.2277) 
Month 3 0.6125 (0.2369) 0.5831 (0.2366) 
Month 6 0.6252 (0.2459) 0.5901 (0.2435) 
Month 12 0.6338 (0.2450) 0.6128 (0.2465) 
QALYs (complete cases)   
Unadjusted QALYs gained  
Mean (Standard Deviation) 
0.7223 (0.214) 0.7042 (0.222) 
adjusted QALYs gained  
 
0.7224 0.7040 
 Incremental Analysis 
(Intervention versus Control) 
QALYs gained  
Difference in Means* (95% CI’s) 
[p-value] 
 
-0.014 (-0.053 to 0.025) [p=0.482] 
COST EFFECTIVENESS 
ANALYSIS 
Probability that Treatment is Cost Effective at λ 
Threshold Value (λ)  
Estimate 
NHS 
λ = £0 48% 
λ = £5,000 24% 
λ = £10,000 22% 
λ = £15,000 22% 
λ = £20,000 22% 
λ = £25,000 22% 
λ = £30,000 23% 
λ = £35,000 23% 
λ = £40,000 23% 
NHS, National Health Service, QALY, Quality-Adjusted Life Year. * Mean differences 
adjusted for clustering in cost and QALY outcomes.  
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Supplementary figures  
 
 
  
S1 Figure: Cost-effectiveness acceptability curve for the comparison of case-finding versus 
pain only from an NHS perspective based (based on the compete-case dataset) 
 
 
 
 
S2 Figure: Cost-effectiveness acceptability curve for the comparison of case-finding versus 
pain only from an NHS perspective based on the two-stage bootstrap approach (compete-case 
dataset) 
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